Stay Informed on Key Developments

Investor News and Updates

Bill_Ipad

Stay informed about key developments at our company as they happen. Discover our Ad-Hoc Releases and subscribe to our newsletter to receive the latest news and topics of interest.

181 - 190of 392 News
181 - 190of 392 News
January 07, 2021
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer issues new senior bonds with a volume of 4 billion euros
READ MORE
January 07, 2021
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
READ MORE
January 06, 2021
Leaps by Bayer leads USD 105 million Series B financing in Senti Bio to develop next-generation cell and gene therapies using advanced gene circuit technology platform
READ MORE
December 07, 2020
Not intended for U.S. and UK Media
Bayer and Atara Biotherapeutics enter strategic collaboration for next generation, mesothelin-targeted CAR-T cell therapies for solid tumors
READ MORE
December 02, 2020
Bayer establishes Cell and Gene Therapy Platform to accelerate pharmaceutical innovation
READ MORE
December 01, 2020
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL
Bayer announces placement of Elanco shares for gross proceeds of 1.6 billion U.S. dollars at completion
READ MORE
November 17, 2020
Not intended for U.S. and UK Media - Late-Breaking Data from subgroup analysis of Phase III FIDELIO-DKD study presented at the American Heart Association (AHA) Scientific Sessions 2020
Finerenone showed consistent benefits on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes with or without history of cardiovascular disease
READ MORE
November 13, 2020
Not intended for U.S. and UK Media
Positive CHMP opinion for extension of rivaroxaban marketing authorization to treat venous thromboembolism (VTE) in children
READ MORE
November 12, 2020
Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund
READ MORE
November 09, 2020
Not intended for U.S. and UK Media
Bayer submits marketing authorization applications for finerenone in the U.S. and the EU for patients with chronic kidney disease and type 2 diabetes
READ MORE
181 - 190of 392 News
181 - 190of 392 News
Inform Yourself on Special Topics
Control Weeds Not Farming

Control Weeds, Not Farming

LEARN MORE
Farmers discussing their weed management

Everything You Need to Know About Glyphosate

LEARN MORE
some-bayer-group-headquarters

Managing Glyphosate Litigation

learn more
woman harvesting carrots

Managing and Mitigating PCB Litigation Risk

learn more